Kyverna Therapeutics, Inc.KYTXNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank36
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Latest
-3.77%
↓ 100% vs avg
Percentile
P36
Within normal range
Streak
1 qtr
Consecutive growthRecovering
Average
8806.28%
Historical baseline
PeriodValue
Q3 2025-3.77%
Q2 2025-13.84%
Q1 202531.98%
Q4 2024-4.05%
Q3 202428.84%
Q2 2024105641.96%
Q1 2024-99.86%
Q4 202359.74%
Q3 2023-8.94%
Q2 20235.96%
Q1 202337.39%
Q4 20220.00%